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reported better urinary function [M = 93.0 (SD = 10.6) vs. 
80.0 (SD  =  19.1), p ≤ 0.001], less urinary incontinence 
[M = 90.0 (SD  =  14.6) vs. 70.1 (SD  =  28.8), p ≤ 0.001], 
and better sexual function [M = 40.9 (SD = 24.6) vs. 14.8 
(17.7), p ≤ 0.001, clinically relevant] than RP-men. Com-
pared to RT, AS-men reported better sexual function 
[M = 40.9 (SD  =  24.6) vs. 25.8 (SD  =  25.0), p = 0.069]. 
The four groups reported similarly low anxiety levels; the 
number of highly anxious men (STAI ≥ 44) ranged from 8 
to 13%. For all QoL domains, men on AS and men without 
PCa reported very similar scores.
Conclusions Prostate-specific function of AS-men was 
significantly better than that of RP-men. When compar-
ing AS to RT, a borderline significant difference in sexual 
function was seen. Men who followed an AS strategy for 
a long-term period were not anxious and accepted it well, 
suggesting that AS may be a good treatment option for men 
with low-risk PCa.
Keywords Active surveillance · Quality of life · Patient 
reported outcome · Radical prostatectomy · Radiotherapy · 
Shared decision-making
Introduction
Men diagnosed with low-risk prostate cancer (PCa) gener-
ally have three therapy options: radical prostatectomy (RP), 
radiotherapy (RT), or active surveillance (AS). Curative 
therapies, like RP and RT, are associated with side-effects, 
such as incontinence and impotence, while AS is aimed at 
deferring such side-effects by opting for an initial monitor-
ing strategy [1]. With AS initial curative therapy is delayed, 
or avoided, and replaced by regular follow-up visits using 
prostate-specific antigen (PSA), digital rectal examination 
Abstract 
Purpose To compare long-term (4–10 years) quality 
of life (QoL) of men with low-risk prostate cancer (PCa) 
treated by different modalities and a reference group with-
out PCa.
Methods In this cross-sectional study, four groups were 
sent a one-time QoL-questionnaire; PCa patients (1) fol-
lowing the structured Prostate cancer Research Interna-
tional Active Surveillance protocol, (2) who underwent 
radical prostatectomy (RP) in the context of the European 
Randomized study of Screening for Prostate Cancer—sec-
tion Rotterdam, (3) who underwent radiotherapy (RT) at 
an academic hospital in The Netherlands, and (4) an age-
matched reference group of men without PCa. The QoL-
questionnaire addressed prostate-specific health (EPIC), 
generic health (SF-12), and anxiety (STAI-6). Statistical 
significance (p ≤ 0.05) and clinical relevance (≥0.5 SD) of 
differences between groups were assessed.
Results The AS, RP, RT, and reference group response 
rates amounted to 74% (122/165), 66% (70/106), 66% 
(221/335), and 75% (205/273), respectively. At a mean 
of 6.6 years of follow-up, active surveillance (AS)-men 
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(DRE), prostate biopsy, and—potentially—magnetic reso-
nance imaging (MRI). Choosing AS, however, requires liv-
ing with untreated cancer and coping with the possibility of 
missing the ‘window of curability’.
AS is reported to be safe [2, 3]. In a 15-year time frame, 
among men that underwent AS in the Sunnybrook cohort, 
2.8% developed metastases and 1.5% died of PCa; this 
mortality rate being consistent with that of favourable-risk 
patients managed with the initial curative therapy [4]. AS 
is now included in many guidelines as a treatment option 
for men diagnosed with low-risk PCa, and over the years, 
the number of men choosing AS has been rising [2, 3, 5–7]. 
The need to understand the effect of AS on well-being of 
men is becoming more apparent now.
In a recent systematic review, Bellardita and colleagues 
concluded that, so far, no major perturbations in the health-
related quality of life (QoL) and psychological well-being 
of men on AS were seen over a follow-up period of 9–36 
months [8]. However, QoL research amongst men on AS 
is still scarce compared to RP and RT QoL research, and 
current AS studies show some methodological drawbacks 
like the infrequent use of comparator groups, the lack of 
an appropriate non-cancer control group, and the use of 
various QoL measures which hinders comparison of QoL 
across treatment groups [8–10]. Furthermore, long-term 
patient reported outcomes are scarce. We aim to fill this 
gap by assessing long-term, i.e. 4–10 year, QoL of men 
with low-risk PCa who were either treated with AS, RP, 
or RT. We included an age-matched group of men without 
PCa as a reference group. All groups completed the same 
set of QoL measures. With the outcomes of this study, we 
would like to support patients and clinicians in weighing 
the advantages and disadvantages of therapies for low-risk 
PCa in terms of QoL, enabling an upfront informed treat-
ment-choice which better reflects patients’ expectations and 
preferences relating to (side) effects of treatment [11].
Patients and methods
Study population
In this cross-sectional study, we compared QoL of early 
diagnosed, low-risk PCa patients and a reference group of 
men without cancer.
1. AS: Men who were diagnosed with low-risk PCa in the 
ERSPC trial (20%) or in clinical practice (80%) choose 
AS and participated in the Prostate cancer Research 
International: Active Surveillance (PRIAS) study [12]. 
Its inclusion criteria are: Prostate-Specific Antigen 
(PSA) ≤10  ng/ml, PSA-density <0.2, clinical Tstage 
T1c-T2, Gleason score 3 + 3 = 6, one or two biopsy 
cores invaded with PCa [13]. 165 participants from 11 
Dutch hospitals (academic or non-academic) with ≥4 
years of follow-up and still on AS were invited to par-
ticipate.
2. RP: men who were diagnosed with low-risk PCa in the 
screening arm of the European Randomized study of 
Screening for Prostate Cancer (ERSPC), Rotterdam 
[14]. The 106 men invited to participate in this QoL 
study were diagnosed with Gleason ≤7 PCa, underwent 
RP, and had ≥4 years of follow-up.
3. RT: men who were diagnosed with low-risk PCa in the 
ERSPC trial (37%) or in clinical practice (63%) and 
underwent RT (HDR-brachytherapy as boost followed 
by external radiation, HDR-brachytherapy as mono-
therapy, or stereotactic body RT with Cyberknife) in 
Erasmus Medical Center, Rotterdam. 335 patients with 
≥ 4 years of follow-up were invited to participate in 
this QoL study.
4. Reference group without PCa: 273 ERSPC Rot-
terdam screening arm participants were randomly 
selected from a group of 1251 who were last screened 
in 2012–2014. In a period of ≥15 years, participants 
were screened four or five times and no PCa was found. 
Based on date of birth, this group was age-matched to 
the AS, RP, and RT groups.
Men were sent an informed consent form and a one-time 
QoL-questionnaire in February 2015. After 1 month, one 
reminder was sent. This study was approved by the Insti-
tutional Review Board of the Erasmus University Medical 
Center (MEC number 2014-596).
Measures included in the questionnaire
A set of validated measures was used to evaluate prostate-
specific health (Expanded Prostate cancer Index Compos-
ite—EPIC), generic health (Short-Form Health-Survey—
SF-12, EQ visual analogue scale—EQ-VAS), and generic 
anxiety (State-Trait Anxiety Inventory—STAI-6).
The EPIC [15, 16] includes 21 items on function and 
bother in the urinary, bowel, and sexual domains with 
scores ranging from 0 to 100. Higher scores reflect bet-
ter functioning. Because incontinence is more related to 
RP and irritative/obstructive symptoms are more related 
to RT, we also assessed the incontinence and irritative/
obstructive subscales [16]. We furthermore report distinc-
tive items from the urinary and sexual domains because of 
their relevance in daily clinical practice for both patient and 
physician.
The SF-12 consists of 12 items with which the physi-
cal (PCS) and the mental component summary score 
(MCS) can be calculated, both ranging from 0 to 100, 
with 100 indicating best health [17]. In addition, the 
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EQ-VAS was used, recording self-rated health on a verti-
cal ‘thermometer’ with endpoints labelled as 100, indi-
cating ‘best imaginable health state’ and 0, indicating 
‘worst imaginable health state’ [18].
Finally, generic anxiety scores assessed through the 
STAI-6 range from 20 to 80; a higher score indicates 
more anxiety. An individual is considered highly anx-
ious in case of a STAI-6 score ≥44 [19, 20].
Statistical analysis
We report mean and standard deviation (SD) of patient 
reported outcomes per group. First, the significance 
of differences in terms of QoL and symptoms between 
all groups were tested using ANOVA. To assess which 
groups were statistically significantly different from each 
other, the ANOVA Tukey post hoc test was performed. 
Exploring differences further, we compared outcomes 
between the three treatment groups using ANCOVA 
(Bonferroni post hoc test), including the covariates age, 
PSA at diagnosis, cTstage, Gleason score, and follow-up 
time. P values (two-sided) ≤0.05 were considered statis-
tically significant. The clinical relevance of observed dif-
ferences was assessed with differences ≥0.5 SD consid-
ered clinically relevant [21]. Analyses were performed 
with SPSS, version 21 (IBM, Armonk, NY, USA).
Results
The AS, RP, RT, and reference group response rates 
amounted to 74% (122/165), 66% (70/106), 66% (221/335), 
and 75% (205/273), respectively (Fig.  1). Patterns in the 
non-response/missing data did not significantly differ 
between participants vs. non-participants. Overall, data of 
four patients were excluded because of completion of ≤50% 
of questions and data of two men on AS were excluded, as 
they no longer followed the AS protocol at the time of ques-
tionnaire completion. Table 1 depicts participants’ clinical 
characteristics at time of diagnosis and demographic char-
acteristics at time of questionnaire sending. Participants’ 
ages at time of questionnaire sending ranged from 72 to 
76 years (SD = 1.6–6.4 years) and the mean follow-up time 
ranged from 6 to 8.6 years (SD = 1.5–3.4 years). The AS 
group had somewhat more favourable clinical characteris-
tics at diagnosis than the radical treatment groups.
Prostate-specific health (EPIC)
Urinary domain
The AS (M = 93.0, SD = 10.0) and RT (M = 89.7, 
SD = 16.2) groups reported significantly better urinary 
function than the RP group (M = 80.0, SD = 19.1) [F 
(3,608) = 16.2, p < 0.001] (Table 2).
The AS (M = 90.0, SD = 14.6) and reference (M = 90.4, 
SD = 13.9) groups less often reported urinary incontinence 
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Fig. 1  Patient cohort selection
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than the RP (M = 70.1, SD = 28.8) and RT groups 
(M = 86.5, SD = 20.3) [F (3,608) = 17.2, p < 0.001]. Com-
paring RT to RP, the RT group reported less urinary incon-
tinence (M = 86.5, SD = 20.3 vs. M = 70.1, SD = 28.8). 
Differences between the AS&RP (p < 0.001) and RP&RT 
(p < 0.001) groups were statistically significant. In the RP 
group, 38% reported to use pads or diapers on a daily basis, 
versus 8% in the RT group, 7% in the AS group, and 5% in 
the reference group (Fig. 2). The urinary bother scores of 
the four groups were rather similar.
Bowel domain
Mean bowel function scores of men with PCa (AS: 
M = 95.7, SD = 6.0; RP: M = 92.6, SD = 9.2; RT: M = 93.0, 
SD = 9.1) were similar to that of men without PCa 
(M = 94.4, SD = 8.5) (Table 2).
Sexuality domain
Significant and clinically relevant differences were seen in 
the overall comparison (Sexual summary: F (3,605) = 4, 
p = 0.01; Sexual function: F (3,555) = 6.8, p < 0.001) 
as well as in AS&RP (sexual summary p = 0.01, sex-
ual function p < 0.001) and RP&RT (sexual function 
p = 0.05) comparisons. The sexual function score was 
highest in men on AS (M = 40.9. SD = 24.6) and lowest 
for men who underwent RP (M = 14.8, SD = 17.7), indi-
cating worst function. Sexual bother scores did not differ 
statistically between groups (Table  2), but large differ-
ences were seen with respect to the firmness of the erec-
tion and the amount of any sexual activity (Fig. 2).
Table 1  Medical and demographic characteristics of participants at the moment of diagnosis, by treatment type
*Significance tested with ANOVA for all four groups where applicable and three groups for the clinical characteristics
AS RP RT Reference group P value*
Number of participants 120 69 219 204
Age at treatment (mean, SD) 65.3 (6.4) 70.0 (2.6) 65.9 (6.2) <0.001
Age at time of questionnaire (mean, SD) 71.9 (6.4) 76.0 (2.6) 74.5 (6.4) 74.5 (1.6) <0.001
Follow-up time in years (mean, SD) 6.6 (1.6) 6.0 (1.5) 8.6 (3.4) <0.001
PSA at diagnosis (mean, SD) 5.9 (3.1) 7.3 (6.1) 7.5 (3.1) <0.001
Clinical stage at diagnosis (n, %)
 T1c 98 (81.7%) 44 (66.7%) 147 (68.1%) 0.012
 T2a 22 (18.3%) 22 (33.3%) 72 (33.3%)
 Missing 0 3 3
Gleason score at diagnosis (n, %)
 4 2 (1.7%) 0 0 <0.001
 5 3 (2.5%) 2 (2.9%) 4 (2.1%)
 6 115 (95.8%) 46 (66.7%) 170 (89.0%)
 7 0 21 (30.4%) 17 (8.9%)
 Missing 0 0 28
Education (n, %)
 Low 30 (25.4%) 21 (31.3%) 57 (26.6%) 73 (35.8%) 0.002
 Intermediate 41 (34.7%) 33 (49.3%) 89 (41.6%) 82 (40.2%)
 High 44 (37.3%) 13 (19.4%) 62 (29.0%) 43 (21.1%)
 Other 3 (2.5%) 0 6 (2.8%) 6 (2.9%)
 Missing 2 2 5 0
Working status (n, %)
 Employed 15 (12.5%) 2 (3.0%) 16 (7.4%) 4 (2.0%) 0.001
 Retired 103 (85.8%) 63 (95.5%) 193 (89.4%) 199 (97.5%)
 Other 2 (1.7%) 1 (1.5%) 7 (3.2%) 1 (0.5%)
 Missing 0 3 3 0
Civil status (n, %)
 Married/living together 105 (87.5%) 53 (79.1%) 181 (83.0%) 177 (86.8%) 0.304
 Other 15 (12.5%) 14 (20.9%) 37 (17.0%) 27 (13.2%)
 Missing 0 2 1 0
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Generic health
The SF-12 PCS score differed significantly between the 
four groups (F (3,558) = 3.2, p = 0.02) (Table  2). The 
ANOVA Tukey post hoc test showed that this differ-
ence was caused by the difference between the AS vs. RT 
comparison (M = 50.7, SD = 6.6 vs. M = 47.8, SD = 8.3, 
p = 0.01) with the AS group reporting better physical func-
tioning. Observed differences were not clinically relevant. 
No significant difference was seen for the mental sum-
mary score. On the EQ-VAS, men on AS rated their health 
best (AS: M = 81.8, SD = 12.7; RP M = 78.6, SD = 15.0; 
RT: M = 78.3, SD = 14.1; Reference: M = 79.5, SD = 12.4) 
(Table 2).
Generic anxiety
Reported levels of generic anxiety were comparable 
amongst the four groups. The percentage of men that may 
be regarded as highly anxious (STAI score ≥ 44) amounted 
to 8% (10/120) in the AS group, 13% (9/69) in the RP 
group, 12% (27/219) in the RT group, and 12% (24/204) in 
the reference group (Table 2).
Comparing active treatment after adjusting for clinical 
parameters
After correcting for age, PSA at diagnosis, cTstage, Glea-
son score, and follow-up time statistically, significant dif-
ferences were found with respect to urinary function, uri-
nary incontinence, urinary irritative, and sexual function 
(Table 3). Bonferroni post hoc test revealed that for urinary 
function and incontinence, it was the AS&RP and RP&RT 
groups that significantly differed from each other. For the 
urinary irritative domain, the RP group had a better score 
than the RT group (M = 99.1, SD = 1.03 vs. M = 90.2, 
SD = 1.02, p = 0.02). Comparing sexual functioning, the 
AS group reported the best score (M = 28.2, SD = 1.14), 
and the RP group the worst (M = 12.2, SD = 1.22) (AS&RP 
p = 0.002, RP&RT p = 0.05).
Discussion
In this paper, long-term patient reported QoL of men on AS, 
men who underwent RP or RT, and a reference group of men 
without prostate cancer was compared. Generic anxiety levels 
were similarly low for all four groups. In this observational 
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Fig. 2  EPIC items on urinary and sexual functioning of relevance for use in daily clinical practice
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study, for the first time, condition-specific function was 
measured with a single patient reported outcome measure 
(EPIC-26) across three treatment groups and a reference 
group without PCa. Statistically significant differences were 
found regarding urinary function and urinary incontinence 
with the AS group reporting better urinary function and less 
incontinence compared to the RP group. A statistically and 
clinically relevant (≥0.5SD) difference was found regarding 
sexual function. When comparing AS to RT, a statistically 
significant difference was seen regarding sexual function, 
with the AS group reporting better sexual function. This dif-
ference was, however, not clinically relevant. These observed 
differences in prostate-specific functioning between treatment 
groups could be expected, as AS has a less invasive character 
than RP and RT. Results furthermore indicate that the QoL of 
men on AS was very comparable to that of men without PCa.
Our data showed that only few men, i.e., 8% in the AS 
group, 12% in the RT and reference group, and 13% in the 
RP group, reported high levels of anxiety. There is a ten-
dency to assume that men who choose AS and therewith 
live with untreated cancer, combined with the potential of 
missing the window of curability, will experience anxiety. 
Observational studies have shown results of AS cohorts in 
which anxiety levels are low [22, 23] versus studies in which 
anxiety levels of around 20% were seen [9, 24]. These obser-
vational studies involved selected groups of patients who 
chose to follow an AS strategy. In the recently published 
ProtecT trial, a randomized controlled trial in which men 
were randomly allocated to either active monitoring, RP or 
RT, longitudinal 5  year follow-up results were presented. 
With respect to anxiety, measured through the Hospital 
Anxiety and Depression Scale (HADS), no significant dif-
ferences among the treatment groups were seen (p = 0.27), 
suggesting that men on AS are not more anxious than men 
on RP or RT [25]. This might indicate that psychological 
support is less needed for men on AS. However, it should be 
noted that only 62% (1643/2664) of eligible men underwent 
randomization in the ProtecT trial, while 38% selected their 
own treatment (based on own or urologist preferences). Fur-
thermore, men who were randomized to active monitoring 
had regular contact with a specialist nurse with whom any 
concerns could be discussed. Furthermore, our data confirm 
the results that Bellardita et al. describe in their review study 
[8], summarizing findings of mainly short-term studies.
Table 3  Quality of life in the active surveillance (AS), radical prostatectomy (RP), and radiotherapy groups (RT) corrected for clinical charac-
teristics (age, PSA at diagnosis, Gleason, cTstage, and follow-up)
SD standard deviation
*Significance tested with ANCOVA with covariates age, PSA at diagnosis, Gleason, cTstage, and follow-up
# ANCOVA Bonferroni post hoc test
AS
Adjusted mean and 
SD
RP
Adjusted mean and 
SD
RT
Adjusted mean and 
SD
All groups
P value*
AS vs. RP
P  value#
AS vs. RT
P  value#
RP vs. RT
P  value#
Generic health
 SF12-PCS 49.6 (1.02) 48.3 (1.03) 47.2 (1.01) 0.126 1.00 0.129 1.00
 SF12-MCS 52.8 (1.02) 51.4 (1.03) 54.2 (1.02) 0.225 1.00 0.993 0.294
Respondent’s self-reported health
 EQ-VAS 79.8 (1.02) 78.3 (1.03) 76.7 (1.02) 0.334 1.00 0.423 1.00
Generic anxiety
 STAI-6 30.7 (1.03) 31.4 (1.04) 32.4 (1.02) 0.283 1.00 0.348 1.00
Prostate-specific health
 EPIC
  Urinary summary 93.3 (1.02) 84.7 (1.03) 87.9 (1.02) 0.016 0.022 0.079 0.869
  Urinary function 91.8 (1.02) 77.8 (1.03) 88.1 (1.02) <0.001 <0.001 0.436 0.001
  Urinary bother 92.5 (1.03) 92.3 (1.04) 89.7 (1.02) 0.682 1.00 1.00 1.00
  Urinary inconti-
nence
88.3 (1.05) 61.4 (1.06) 83.9 (1.04) <0.001 <0.001 1.00 <0.001
  Urinary irritative 95.5 (1.02) 99.1 (1.03) 90.2 (1.02) 0.012 0.956 0.138 0.020
  Bowel summary 99.1 (1.03) 96.8 (1.04) 96.6 (1.02) 0.702 1.00 1.00 1.00
  Bowel function 98.2 (1.03) 94.6 (1.04) 94.8 (1.02) 0.543 1.00 0.902 1.00
  Bowel bother 97.1 (1.03) 98.6 (1.04) 100.0 (1.02) 0.635 1.00 1.00 1.00
  Sexual summary 48.8 (1.07) 33.5 (1.10) 41.6 (1.06) 0.010 0.007 0.268 0.180
  Sexual function 28.2 (1.14) 12.2 (1.22) 21.3 (1.11) 0.003 0.002 0.329 0.045
  Sexual bother 80.9 (1.06) 77.4 (1.08) 78.3 (1.05) 0.893 1.00 1.00 1.00
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Although the RP group reported frequent urinary incon-
tinence and both RP and RT groups reported limited sexual 
function, they reported similar levels of bother as the AS 
and reference groups, with the latter reporting hardly any 
urinary incontinence and better sexual functioning. The pat-
tern of impaired function but no related bother can possi-
bly be explained by response shift [26, 27]. Sprangers and 
Schwartz describe response shift as “a change in the mean-
ing of one’s self-evaluation of QoL as a result of a change in 
one’s internal standards of measurement (i.e., recalibration), 
the importance attributed to component domains constituting 
QoL (i.e., change in values), or construal of the meaning of 
QoL (i.e., concept redefinition) [26, 28].” It may be that over 
time men have accepted the changes in, e.g., their sexual 
functioning, because they perceived these as an inevitable 
consequence of PCa treatment; a condition thought to be life 
threatening by at least a part of men with PCa [27, 29]. As a 
result, men may have changed the importance they attach to 
sexual activity to soften the negative influence of deteriorat-
ing sexual function (i.e., change in values) [28]. Behavioural 
scientists tend to refer to the response shift process as cogni-
tive adaptation [30, 31]. Ageing may play a role as well [32]. 
In addition to the higher prevalence of erectile dysfunction 
in older men, Korfage et  al. found that diminishing sexual 
activity with increasing age was considered more or less nor-
mal amongst a group of treated PCa patients [27, 33].
While patients are often able to adapt to a new situation 
and accept side-effects, it is important to enable them to 
consider potential consequences of treatment beforehand. 
We want to provide relevant PCa treatment information, and 
therewith enable men to base their treatment-choice on what 
they consider important and to avoid those side-effects they 
find least acceptable. The here presented outcomes for the 
three treatments can support men and their physicians in 
deciding what treatment fits the patient best in terms of QoL. 
By discussing, amongst others, the side-effects of each type 
of treatment as well as patients’ preferences, we furthermore 
hope to stimulate shared decision-making between patients 
and physicians, as patient participation may positively affect 
treatment decision-making. A recent study amongst 1529 
men with clinically localized PCa explored whether active 
patient involvement in decision-making and greater patient 
knowledge are associated with better treatment decision-
making experiences and QoL [34]. The authors concluded 
that the men who were knowledgeable about PCa and the 
side-effects of treatment at the time of treatment decision-
making experienced better QoL 6 months after treatment 
because of realistic expectations regarding side-effects [34].
This study has limitations. Differences related to baseline 
clinical and demographic characteristics of the participants 
were seen. Because men were not randomized into treatment 
groups, clinical and demographic characteristics slightly varied 
per group. However, the study design we report does represent 
current clinical practice, where choice for treatment is selec-
tive and individualized. Our findings furthermore highlight the 
importance and need of a baseline, i.e., pre-diagnostic biopsy, 
measurement. Future studies, such as the mixed-method study 
by Ruane-McAteer et al. [35], will, by including such a base-
line measurement, provide further valuable information on the 
impact on QoL of either AS or direct curative treatment on 
both mental and physical health of the patient. The RT group 
in our study is heterogeneous. As we acknowledge that there is 
a difference between brachytherapy and external radiation, we 
stratified QoL outcomes in the individual radiotherapy groups 
(i.e., mono brachytherapy and brachytherapy followed by 
external radiation and Cyberknife) in appendix Table 4. When 
comparing mono brachytherapy with brachytherapy + external 
radiation, mainly, a difference on the sexuality domain was 
seen with the mono brachytherapy group showing better sex-
ual function. In comparing the brachytherapy + external radia-
tion and Cyberknife groups, significantly higher bowel domain 
scores were seen for the Cyberknife group indicating better 
bowel function in the latter group. We furthermore chose an 
age-matched cohort of screening arm participants without PCa 
from the ERSPC Rotterdam study to reflect the general popula-
tion. The previous studies have shown that ERSPC-Rotterdam 
participants differ from the general population, in the sense 
that they seem to be healthier [36, 37]. However, the entire RP 
group, 20% of the AS group, and 37% of the RT group also 
participated in ERSPC Rotterdam. Strengths of our study are 
the considerable length of follow-up of 4–10 years, the good 
questionnaire response rates, the use of one validated patient 
reported outcome measure—the EPIC—to compare prostate-
specific function across all four groups, the inclusion of a non-
PCa reference group, and, for the first time, the reporting of 
long-term QoL results for an AS cohort.
To conclude, in this cross-sectional study, we compared 
long-term QoL of PCa patients on AS to that of PCa patients 
who followed direct curative regimens and a reference group 
of men without PCa. Generic anxiety was similarly low 
amongst all four groups and in terms of prostate-specific 
functioning, the AS group reported better sexual function as 
compared to the RP and RT groups and better urinary func-
tion than the RP group. The QoL of men on AS was very 
comparable to that of men without PCa. Our results indicate 
men who followed an AS strategy for a long-term period 
were not anxious and accepted it well, suggesting that AS 
may be a good treatment option for men with low-risk PCa.
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Table 4  Questionnaire scores per RT-type
SD standard deviation
*3-group comparison: significance tested with ANOVA after log transformation of the scores
# 2-group comparisons: significance tested with T test after log transformation of the scores
Score range HDR-
brachy + exter-
nal
N = 121
HDR-brachy
N = 73
Cyberknife
N = 38
Brachy + exter-
nal vs. brachy
Brachy + exter-
nal vs. 
cyberknife
Brachy vs. 
cyberknife
Mean (SD) Mean (SD) Mean (SD) P value* P  value# P  value# P  value#
Generic health
 SF-12—PCS 0–100 46.6 (8.3) 48.7 (7.6) 49.7 (9.3) 0.191 0.111 0.186 0.824
 SF-12—MCS 0–100 53.6 (8.9) 54.3 (8.6) 58.3 (6.0) 0.028 0.609 0.008 0.019
 EQ-VAS 0–100 77.4 (13.9) 79.0 (14.8) 79.4 (13.5) 0.772 0.571 0.549 0.873
 STAI-6 20–80 34.1 (9.5) 32.9 (7.9) 31.0 (6.2) 0.273 0.493 0.121 0.272
 Highly anxious 
(N, %)
≥44 18 (14.9%) 8 (11.0%) 1 (2.6%)
EPIC
 Urination 0–100, with higher 
scores indicating 
better quality 
of life
  Urinary sum-
mary
88.8 (16.3) 89.8 (13.2) 91.7 (12.1) 0.496 0.513 0.289 0.489
  Urinary func-
tion
88.4 (18.4) 90.3 (14.3) 92.6 (11.4) 0.294 0.352 0.178 0.376
  Urinary bother 89.0 (16.2) 89.4 (13.9) 91.1 (13.9) 0.724 0.702 0.459 0.598
  Urinary inconti-
nence
84.9 (22.3) 86.6 (19.1) 91.5 (14.7) 0.223 0.453 0.105 0.195
  Urinary irrita-
tive
91.8 (13.9) 92.9 (10.5) 91.9 (12.3) 0.708 0.416 0.837 0.621
 Bowel
  Bowel summary 93.3 (8.8) 95.4 (7.4) 97.5 (3.0) 0.024 0.133 0.010 0.136
  Bowel function 91.3 (10.6) 94.0 (7.7) 96.0 (4.5) 0.020 0.073 0.019 0.181
  Bowel bother 95.3 (8.5) 96.7 (7.8) 99.0 (2.9) 0.075 0.341 0.019 0.135
 Sexuality
  Sexual sum-
mary
37.8 (19.6) 45.0 (20.2) 43.2 (21.1) 0.068 0.018 0.242 0.645
  Sexual function 21.0 (23.9) 31.3 (26.0) 29.2 (23.9) 0.069 0.058 0.069 0.752
  Sexual bother 75.7 (26.6) 76.6 (24.8) 74.4 (31.3) 0.992 0.922 0.913 0.969
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